NIR‐II Self‐Luminous Molecular Probe for In Vivo Inflammation Tracking and Cancer PDT Effect Self‐Evaluating. Issue 11 (19th December 2022)

• Record Type: Journal Article
• Authors: Yuan, Meng; Fang, Xiao; Liu, Jianyong; Yang, Kaiqiong; Xiao, Shenggan; Yang, Sheng; Du, Wei; Song, Jibin
• Is Part Of: Small. Volume 19:Issue 11(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-19
• Subjects: activatable probes -- bioluminescence -- biosensing -- NIR‐II imaging -- in vivo bioimaging; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.202206666
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract: Optical imaging in the second near‐infrared (NIR‐II, 900–1700 nm) window has been extensively investigated for bioimaging. However, a strong autofluorescence background from real‐time excitation light significantly reduces the images' quality of NIR‐II fluorescence (FL) imaging. To resolve this issue, a NIR‐II self‐luminous small molecule (CLPD) based on bioluminescence (BL) resonance energy transfer (BRET) mechanism is first developed. The reactive oxygen species (ROS) can trigger NIR‐II BL and reduce the NIR‐II FL signals of the CLPD simultaneously, enabling ROS‐correlated ratiometric BL/FL imaging. CLPD is used for high‐contrast NIR‐II BL imaging of osteoarthritis as well as guiding the treatment process by ratiometric BL/FL imaging. Moreover, CLPD is applied for NIR‐II BL imaging of tumor triggered by the generated ROS during PDT. A correlation between the ratiometric NIR‐II BL/FL signal and tumor size is constructed, providing a trustworthy tool for early assessment of PDT effect. Overall, this study presents a novel NIR‐II self‐luminous small molecular probe for in vivo imaging and provides a strategy for design a self‐evaluation system of therapeutic effect. Abstract : An endogenous‐activated NIR‐II self‐luminous small molecule probe (CLPD) employing BRET effect and redox, offering unique features such as well biocompatibility, high penetration depth, and high signal‐to‐noise ratio is first developed. More importantly, CLPD enables NIR‐II BL/FL bimodal imaging of in vivo inflammation and early prediction of cancer PDT treatment effects.